The 180 FDA
hopeful approval is likely 3rd quarter. So the "big news" that my hobby hazy bowling ball predicts would begin an ascent following the likes of DXCM is within this year.
The common bio/pharma start companies route: The typical leaking boat waiting for the big fix to right itself. # wise, it's overbought.
In my not so wise opinion, I believe their product is a valuable new item for Diabetics that holds a massive global segment of the medical market...
So disclaimers complete (Alert: Hobbyist): Yes, I think it's a good addition/entry point.
The recent uptick was confused with the anticipation / idea FDA (due to influx of April options) is on the cusp, when the reality: A massive patent for remote transmitting of the device (w/o any external patched item) was just approved.
I'd share 1yr / 1 day rsi/MacD, etc though if done from my phone, I'm unable to resize to a small pic.
1yr and 20 day are my personal go-to for review.
We pulled another 1k at the current and have covered calls for April and may for our perspectives account.
I'm on a desktop and transferred my screen-pic over for the 1yr/day
